1. Acumen's $36M Bet: ALTITUDE-AD Phase II Readout Pushed to Late 2026 as EBD Program Advances
Acumen Pharmaceuticals has set a definitive but distant timeline for a critical clinical milestone, targeting a Phase II readout for its Alzheimer's candidate, ALTITUDE-AD, for late 2026. This specific date provides clarity but also underscores the lengthy development runway still ahead for the program. Concurrently, t...